

Pharmacy and Therapeutics Committee

Meeting Minutes

Thursday, June 20, 2019
7:00 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

McKay Robinson, PharmD
Clayton Grace, RPh
Michelle Hofmann, MD
Bryan Larson, PharmD

Clinton Sheffield, MD
Susan Siegfried, MD
Cole Sloan, PharmD
Christopher Valentine, MD

Committee Members Excused:

Elizabeth Young, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Joe Busby, RPh, MBA
Spencer Miller, CPhT
Andrea Rico, CPhT
Cheri Bender, CPhT

Jennifer Strohecker, PharmD, Pharmacy
Director
Dana Bui, CPhT
Julie Armstrong, CPhT

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez Alonso, B.S. Pharm, MSc MTSI

Other Individuals Present:

Shae Wilson, Molina
Mike Cahill, Sobi
Justin Barnes, Ironshore Pharmaceuticals
Olaf Rainwald, Ironshore Pharmaceuticals
Becky Gonzales, ViiV Healthcare
Jennifer Lauper, Bristol-Myers Squibb
Rick Kegler, Otsuka
Jeff Mussack, Otsuka
Lee Stout, Chiesi
Lori Howarth, Bayer
Jess Boucher, Bayer
David Holman, MTPA
Palmer Weaver, Molina
Stephen Kim, University of Utah
Dawn Bina, Novo Nordisk
Emma Chacon, DOH

Pierre Thoumsin, Heron Therapeutics
Karlee Paloukos, UofU
Laura Britton, Healthy U
Cody Ball, SelectHealth
Jason Bott, Lilly
Roy Lindfield, Sunovion
Ron Abraham, Sunovion
Michelle Bice, Gilead
John Slade, OIG
Trevor Smith, DOH
Lisa Wilson, Biogen
Soheyila Azizi, Eisai
Jorge Fuentes, DOH
Patrick Moty, Horizon
Robyn Seely, Health Choice Utah

Pharmacy and Therapeutics Committee

Meeting Minutes

1. **Welcome:** McKay Robinson opened the meeting and announced a quorum.
2. **Review and Approval of March Minutes:** McKay Robinson made a motion to approve the minutes from March. Cole Sloan seconded the motion. Five in favor, with Christopher Valentine abstaining, motion passed. Clinton Sheffield was not present for this vote.
3. **Housekeeping:** Bryan Larson reported that an update to the Long-Acting Insulins class on the PDL will go live on July 1st, 2019 in response to the motion made by the P&T Committee at the March meeting.
4. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Opioid Policy. DUR board reviewed opioid policy for the Medicaid pharmacy program and interventions to support Retrospective DUR (RetroDUR) work. University of Utah providing annual DUR work and RetroDUR work. This includes Outreach programs for high cost claims, risk profile assessment, and targeted interventions. DUR Committee will continue looking at SUPPORT Act requirements; specifically the use of MMEs, use of opioids and antipsychotics, and monitoring and management of high-risk combinations and antipsychotics in children.
5. **Accountable Care Organization (ACO) Update:** Report of Methodologies for Preferred Drug list.
 - a. HealthyU.....Laura Britton, PharmD
 - b. Molina.....Shea Wilson, RPh
 - c. Select Health.....Cody Ball PharmD, MBA, BCPS, ATC
 - d. Health Choice.....Robyn Seely, BS, PharmD, RPh
6. **ADHD Stimulant Review:** (amphetamine, dexamethylphenidate, dextroamphetamine, dextroamphetamine/amphetamine mixed salts, lisdexamfetamine, methamphetamine, methylphenidate). Elena Martinez presented a review of ADHD Stimulant products. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines, and Utah Medicaid utilization data. Comparative benefits of long-acting versus short-acting formulations were shown in the review. Guidelines were presented in respect to treatment of ADHD in children, adolescents, and adults. Adverse events, potential abuse, and individualized patient care were discussed.
7. **Public Comment:**
 - a. Justin Barnes, Medical Science Liaison from Ironshore Pharmaceuticals, presented information pertaining to Jornay PM.
8. **ADHD Stimulant Discussion:**
 - a. The committee discussed dosing of immediate release and extended release

Pharmacy and Therapeutics Committee

Meeting Minutes

products.

- b. Clinton Sheffield made a motion to maintain the current recommendations with an amendment ensuring that there is at least one immediate release and at least one extended release from both amphetamines and methylphenidates for those who have trouble swallowing. Bryan Larson seconded the motion. Unanimous approval, motion passed.
9. **Sedative Hypnotics Review** (Non-Benzodiazepines, Non-Barbiturates). Valerie Gonzales presented a review of Sedative Hypnotics. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines, and Utah Medicaid utilization data.
10. **Sedative Hypnotics Discussion:**
- a. Christopher Valentine made a motion to have the DUR board review tasimelteon (Hetlioz). Clinton Sheffield seconded the motion. Unanimous approval, motion passed.
 - b. Susan Siegfried made a motion have at least one agent for sleep onset and one for sleep maintenance included on the PDL. Clayton Grace seconded the motion. Unanimous approval, motion passed.
11. **Public Meeting Adjourned:** Bryan Larson motioned to close the meeting. McKay Robinson seconded the motion. Unanimous Approval.
12. **Next meeting is scheduled for** September 19, 2019 Cytokine Inhibitors.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>